[144] UNITED THERAPEUTICS Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics (UTHR) insider sale notice: An officer/director-level holder filed a Form 144 to sell 4,000 common shares with an aggregate market value of $1,795,655.20 planned on 10/09/2025 through TD Securities (USA) LLC on the NASDAQ. The filing shows these shares were originally acquired on 03/15/2016 via executive deferred compensation from Martine Rothblatt and were exercised via vested options with payment made in common shares. The filing also lists multiple recent disposals of common shares by Martine Rothblatt on dates across 09/09/2025 to 10/08/2025, each transaction showing 4,000 shares on most dates and one 8,000-share sale on 09/09/2025, with individual gross proceeds reported per trade. The filer certifies no undisclosed material adverse information and includes routine signature/attestation language.

Positive

• Transparent disclosure of the planned sale and detailed recent sale history in compliance with Rule 144
• Sales tied to exercised vested options from 03/15/2016, indicating monetization of long-held compensation rather than new insider purchases

Negative

• Frequent sales by the same insider across 09/09/2025 to 10/08/2025 could be perceived negatively by some investors
• No Rule 10b5-1 plan date provided in the filing, so it is unclear if sales follow a pre-established trading plan

Insights

Equity Markets Analyst

Insider selling is active across Sept–Oct 2025 but shares sold per trade are modest relative to institutional blocks.

Repeated sales by the same insider on multiple dates indicate a staged liquidation approach rather than a single large block sale. The planned sale of 4,000 shares for $1,795,655.20 on 10/09/2025 is routed through TD Securities on the NASDAQ, which is consistent with market‑order execution through a broker‑dealer.

Key dependency: the market impact depends on daily trading volume and whether additional filings disclose larger aggregated disposals; watch subsequent Form 4s or 144s in the next 1–2 weeks for further sales activity.

Corporate Governance Analyst

Sales originate from exercised vested options tied to executive deferred compensation dating to 2016.

The acquisition via executive deferred compensation and exercise of vested options on 03/15/2016 explains why these holdings are now being sold; the filer attests there is no undisclosed material information as required by the form.

Governance implication: routine monetization of long-held option proceeds is disclosed; monitor whether these are isolated liquidity events or part of an ongoing plan by checking if a Rule 10b5-1 trading plan date is later provided in filings within the next quarter.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20th Floor NEW YORK NY 10017	4000	1795655.20	45230000	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672592.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736488.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723739.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/26/2025	4000	1712891.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/29/2025	4000	1702526.76
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/30/2025	4000	1691357.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/01/2025	4000	1701796.53
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/02/2025	4000	1739525.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/03/2025	4000	1784847.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/06/2025	4000	1798765.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/07/2025	4000	1807320.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/08/2025	4000	1803449.20

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 for UTHR report?

It reported a proposed sale of 4,000 common shares with aggregate market value $1,795,655.20 planned on 10/09/2025 through TD Securities on NASDAQ.

Who is selling the United Therapeutics shares (UTHR)?

The filing identifies Martine Rothblatt as the person whose account the securities are to be sold and shows prior sales by the same individual.

How were the sold shares originally acquired?

The securities to be sold were acquired on 03/15/2016 under executive deferred compensation and were exercised via vested options with payment made in common shares.

Did the filer disclose recent sales activity?

Yes; the filing lists multiple sales by date from 09/09/2025 through 10/08/2025, including an 8,000-share sale on 09/09/2025 and several 4,000-share sales thereafter, with gross proceeds shown for each trade.

Does the Form 144 indicate any undisclosed material information?

The signer represents they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.